• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New Advances in Healthcare AI Could Unlock Billions in Market Opportunity

    4/29/25 11:29:00 AM ET
    $AMST
    $CLOV
    $GOOG
    $GOOGL
    Computer Software: Prepackaged Software
    Technology
    Medical Specialities
    Health Care
    Get the next $AMST alert in real time by email

    USA News Group News Commentary

    Issued on behalf of Avant Technologies Inc.

    VANCOUVER, BC, April 29, 2025 /CNW/ -- Artificial intelligence is making deeper inroads into western healthcare, targeting the slow grind of authorizations and paperwork that bog down patient care. Despite Bill Gates' prophecy about AI replacing doctors, the real push today is about supercharging physicians, not sidelining them. Recent moves by players such as like Avant Technologies, Inc. (OTCQB:AVAI), Amesite Inc. (NASDAQ:AMST), Oracle Corporation (NYSE:ORCL), Clover Health Investments, Corp. (NASDAQ:CLOV), and Alphabet Inc. (NASDAQ:GOOG, GOOGL)) are signaling just how fast this transformation is taking hold.

    USA News Group logo (PRNewsfoto/USA News Group)

    The article continued: Meanwhile, Barclays projects the healthcare AI market will surge at a 30% compound annual growth rate through 2030, fueled by a wave of new investment across hospitals, insurers, and pharma. A Deloitte survey echoes the optimism, with 71% of healthcare leaders expecting better profits this year as AI tools scale across systems.

    Avant Technologies and Ainnova Request Pre-Submission Meeting with US FDA for VisionAI Platform Technology 

    Avant Technologies, Inc. (OTCQB:AVAI), an emerging leader in AI-driven healthcare innovation, and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that The Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) has received the company's submission package requesting a pre-submission meeting with the FDA for its VisionAI platform technology and is now under review.

    Ainnova is requesting a pre-submission meeting with the FDA's review team to discuss any questions and/or concerns about its proposed formal submission, including seeking advice to finalize the protocol and obtain agency guidance for a clinical trial of its VisionAI platform in the early detection of diabetic retinopathy. A pre-submission meeting allows companies to clarify regulatory requirements, get feedback on their plans, and potentially avoid delays or issues during the formal review process.

    The clinical studies will aim to support an FDA 510(k) submission to obtain clearance from the regulatory agency to market its technology in the U.S.

    Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, including its VisionAI platform and its versatile retinal cameras, has worldwide licensing rights for this portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States.

    "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where VisionAI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market," said Vinicio Vargas, CEO at Ainnova and a member of AAC's Board of Directors. "Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product."

    For medical device applicants like Ainnova, the FDA's pre-submission program is useful to determine a clear regulatory pathway for the successful launch of the device, including the number of patients and the number of clinics that will be needed to generate the necessary clinical data for the FDA to make an informed decision on Ainnova's VisionAI platform.

    For Avant, the pre-submission meeting will help define a precise budget for the strategic partnership's entire FDA process.

    This follows Ainnova's recent strategic alignment with Apollo Hospitals in Southeast Asia, where the Vision AI platform has been cleared for commercial deployment in Brazil, and clinical pilots are being prepared across the Americas. Avant and Ainnova have identified Brazil and the United States as key strategic markets. Ainnova is currently addressing regulatory pathways in Brazil with the support of its MDSAP certification to meet ANVISA requirements, paving the way for rapid market entry.

    Ainnova is being guided by global CRO Fortrea ahead of the important pre-submission meeting with the FDA. The goal is to seek 510(k) clearance for Vision AI in detecting diabetic retinopathy, a gateway to broader use across multiple chronic disease categories.

    Between FDA progress, high-profile alliances, and a growing international presence, Avant Technologies continues to carve out a niche in the convergence of AI, diagnostics, and preventative care. Investors looking for small-cap exposure to the healthcare AI revolution may want to keep AVAI on the radar as these developments unfold.

    CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

    Amesite Inc. (NASDAQ:AMST) recently extended HIPAA compliance for its NurseMagic™ platform to cover individual users as well as enterprise clients. Healthcare providers can now safely use NurseMagic™ to store patient data, helping to reduce documentation time while protecting sensitive information.

    "Meeting HIPAA requirements for all of our users is a natural extension of what we've already provided to enterprise customers," said Kalie Wortinger, Senior Manager of Engineering at Amesite. "We operate in a highly regulated industry, where protecting sensitive data is essential. This expansion reinforces our commitment to trust, privacy, and long-term value—for individual users, organizations, and their patients."

    The platform's flexibility allows users to integrate AI-generated notes into any existing electronic medical record system.

    Oracle Corporation (NYSE:ORCL) recently revealed that North York General Hospital is the first hospital in Canada to migrate its electronic health record system to Oracle Cloud Infrastructure (OCI). The move has significantly decreased system latency, improved login and transaction times, and enhanced disaster recovery protections.

    "North York General Hospital is on a mission to set new standards for people-centered care through integrated and coordinated patient services across the organization, and its recent migration to OCI provides the foundation required to achieve that goal," said Erin O'Halloran, vice president and Canada market leader, Oracle Health. "Leveraging OCI's regional footprint in Canada to store and process data has helped NYGH bolster its resilience, improve its scalability, and helped it implement strategic approaches to disaster recovery."

    These upgrades are helping clinicians work more efficiently and spend more time with patients. By leveraging OCI, NYGH is positioning itself to advance innovation in healthcare through real-time data and AI technologies.

    Clover Health Investments, Corp. (NASDAQ:CLOV) recently announced that its subsidiary, Counterpart Health, is partnering with Alphabet Inc. (NASDAQ:GOOG, GOOGL)) through Google Cloud to enhance its Counterpart Assistant platform.

    "Physicians are often under-resourced and lack access to cutting-edge technologies that can simplify care delivery," said David Tsay, MD, chief medical officer at Counterpart. "Our goal with Counterpart Assistant is to bring all the leading edge tools under one roof, layer them over a single source of normalized data, and give clinicians what they need to make informed decisions—without the burden of fragmented solutions."

    By integrating Google Cloud's Vertex AI Search, the platform enables physicians to quickly access unified patient records and receive AI-generated clinical insights. The collaboration is designed to streamline clinical workflows, reduce administrative burdens, and support better outcomes in value-based care.

    "Clinicians are spending nearly 28 hours a week on administrative tasks, and 82% are reporting burnout," said Aashima Gupta, global director of Healthcare Strategy & Solutions, Google Cloud. "Gen AI-powered search can help alleviate some of this burden, and Counterpart Health's integration of Vertex AI Search will empower physicians to access critical patient information quickly and efficiently, helping them refocus on what matters most: better patient care."

    Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

    CONTACT:

    USA NEWS GROUP

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Logo: https://mma.prnewswire.com/media/2603685/5292786/USA_News_Group_Logo.jpg

    SOURCE USA News Group

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/29/c9707.html

    Get the next $AMST alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AMST
    $CLOV
    $GOOG
    $GOOGL

    CompanyDatePrice TargetRatingAnalyst
    Oracle Corporation
    $ORCL
    7/17/2025$300.00Sector Outperform
    Scotiabank
    Alphabet Inc.
    $GOOGL
    7/15/2025$200.00 → $208.00Outperform
    BMO Capital Markets
    Oracle Corporation
    $ORCL
    7/10/2025$270.00Neutral → Overweight
    Piper Sandler
    Oracle Corporation
    $ORCL
    7/2/2025$235.00 → $245.00Outperform
    BMO Capital Markets
    Oracle Corporation
    $ORCL
    6/30/2025$250.00Hold → Buy
    Stifel
    Alphabet Inc.
    $GOOGL
    6/27/2025$172.00Outperform → Neutral
    BNP Paribas Exane
    Alphabet Inc.
    $GOOGL
    6/27/2025$220.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Oracle Corporation
    $ORCL
    6/18/2025$220.00 → $250.00Buy
    Guggenheim
    More analyst ratings

    $AMST
    $CLOV
    $GOOG
    $GOOGL
    SEC Filings

    See more
    • SEC Form 144 filed by Alphabet Inc.

      144 - Alphabet Inc. (0001652044) (Subject)

      7/18/25 4:47:18 PM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 144 filed by Alphabet Inc.

      144 - Alphabet Inc. (0001652044) (Subject)

      7/18/25 4:46:59 PM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 8-K filed by Alphabet Inc.

      8-K - Alphabet Inc. (0001652044) (Filer)

      7/18/25 4:16:46 PM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology

    $AMST
    $CLOV
    $GOOG
    $GOOGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Oracle with a new price target

      Scotiabank initiated coverage of Oracle with a rating of Sector Outperform and set a new price target of $300.00

      7/17/25 8:08:11 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • BMO Capital Markets reiterated coverage on Alphabet A with a new price target

      BMO Capital Markets reiterated coverage of Alphabet A with a rating of Outperform and set a new price target of $208.00 from $200.00 previously

      7/15/25 9:29:54 AM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology
    • Oracle upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Oracle from Neutral to Overweight and set a new price target of $270.00

      7/10/25 8:27:04 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $AMST
    $CLOV
    $GOOG
    $GOOGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: CEO of Home Care Priest Brady Patrick was granted 379,867 shares and covered exercise/tax liability with 48,305 shares, increasing direct ownership by 15% to 2,496,438 units (SEC Form 4)

      4/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      7/22/25 4:37:26 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Director Shriram Kavitark Ram sold $6,235,220 worth of shares (33,566 units at $185.76), decreasing direct ownership by 7% to 243,400 units (SEC Form 4)

      4 - Alphabet Inc. (0001652044) (Issuer)

      7/21/25 4:47:16 PM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology
    • Director Seligman Naomi O sold $770,656 worth of shares (3,303 units at $233.32), decreasing direct ownership by 10% to 31,447 units (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      7/18/25 4:26:23 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $AMST
    $CLOV
    $GOOG
    $GOOGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 22, 2025 /PRNewswire/ -- USA News Group News Commentary – The AI revolution in healthcare is fully underway, with the potential to save lives and money, but there's still more to come. Healthcare startups are already figuring out how to implement AI to multiply their patients, and chase profits, to the benefit of investors. More Americans than ever are utilizing AI to diagnose their health issues, as the adoption of AI tools is becoming the norm among medical professionals. Now the developers of these game-changing technologies are overcoming regulatory barriers and moving closer to implementation o

      7/22/25 9:15:00 AM ET
      $AGEN
      $CLOV
      $MGRM
      $ZBH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
      Medical/Dental Instruments
    • Clover Health to Participate in Upcoming Canaccord Genuity 45th Annual Growth Conference

      WILMINGTON, Del., July 21, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that its Chief Financial Officer, Peter Kuipers, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 11:00 a.m. Eastern Time. A live webcast and replay of the presentation will be accessible from Clover Health's investor relations website at https://investors.cloverhealth.com/. About Clover Health:Clover Health (NASDAQ:CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have

      7/21/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Appoints Joseph Oldakowski as Vice President of Finance and Controller

      WILMINGTON, Del., July 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement company bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph (Joe) Oldakowski as Vice President of Finance and Controller. In this role, Mr. Oldakowski reports to Chief Financial Officer Peter Kuipers and will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax function. Mr. Oldakowski, who joined Clover Health in June, brings nearly two decades of experience in finance and accounting leadership across the healthcare and insurance sectors. He most recently served a

      7/17/25 8:30:00 AM ET
      $CLOV
      Medical Specialities
      Health Care

    $AMST
    $CLOV
    $GOOG
    $GOOGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fairhead Rona Alison bought $112,258 worth of shares (480 units at $233.87), increasing direct ownership by 2% to 22,110 units (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      7/9/25 4:39:51 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Director Boskin Michael J bought $111,145 worth of shares (1,682 units at $66.08), increasing direct ownership by 2% to 92,458 units (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      3/21/25 8:43:30 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Director Moorman Charles W bought $947,913 worth of shares (5,500 units at $172.35) (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      2/14/25 4:41:16 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $AMST
    $CLOV
    $GOOG
    $GOOGL
    Financials

    Live finance-specific insights

    See more
    • Clover Health to Report Second Quarter 2025 Financial Results on August 5, 2025

      WILMINGTON, Del., July 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Tuesday, August 5, 2025. Company management will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. Second Quarter 2025 Conference Call and Webcast Details: What: Clover Health's Second Quarter 2025 Earnings Conference CallWhen: Tuesday, August 5, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-245-3047 (for U.S. caller

      7/8/25 8:30:00 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • Oracle Announces Fiscal 2025 Fourth Quarter and Fiscal Full Year Financial Results

      Q4 Remaining Performance Obligations up 41% to $138 billionQ4 GAAP Earnings per Share $1.19, non-GAAP Earnings per Share $1.70Q4 Total Revenue $15.9 billion, up 11%Q4 Cloud Revenue (IaaS plus SaaS) $6.7 billion, up 27%Q4 Cloud Infrastructure (IaaS) Revenue $3.0 billion, up 52%Q4 Cloud Application (SaaS) Revenue $3.7 billion, up 12%Q4 Fusion Cloud ERP (SaaS) Revenue $1.0 billion, up 22%Q4 NetSuite Cloud ERP (SaaS) Revenue $1.0 billion, up 18%FY 2025 Total Revenue $57.4 billion, up 8%AUSTIN, Texas, June 11, 2025 /PRNewswire/ -- Oracle Corporation (NYSE:ORCL) today announced fiscal 2025 Q4 and full-year 2025 results. Total quarterly revenues were up 11% year-over-year in USD and constant curren

      6/11/25 4:05:00 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Oracle Sets the Date for its Fourth Quarter Fiscal Year 2025 Earnings Announcement

      Earnings Results to be released on June 11, 2025, After the Close of the Market AUSTIN, June 3, 2025 /PRNewswire/ -- Oracle Corporation today announced that its fourth quarter and fiscal year 2025 results will be released on Wednesday, June 11th, after the close of the market.  Oracle will host a conference call and live webcast at 4:00 p.m. Central Time to discuss the financial results.  The live webcast will be available on the Oracle Investor Relations website at www.oracle.com/investor. About Oracle Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE:ORCL), please visit us at www.oracle.com.

      6/3/25 4:00:00 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $AMST
    $CLOV
    $GOOG
    $GOOGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Clover Health Appoints Joseph Oldakowski as Vice President of Finance and Controller

      WILMINGTON, Del., July 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement company bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph (Joe) Oldakowski as Vice President of Finance and Controller. In this role, Mr. Oldakowski reports to Chief Financial Officer Peter Kuipers and will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax function. Mr. Oldakowski, who joined Clover Health in June, brings nearly two decades of experience in finance and accounting leadership across the healthcare and insurance sectors. He most recently served a

      7/17/25 8:30:00 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Set to Join Russell 3000® Index

      WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part of the 2025 Russell indexes reconstitution. Annual reconstitution of the Russell indexes captures the 4,000 largest US stocks as of April 30, 2025, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, also results in automatic membership in the large-cap Russell 1000® Index or small-cap Russell 2000® Index along with the relevant growth and value style indexes. FTSE Russe

      6/30/25 8:30:00 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Appoints Industry Veteran as Chief Medical Officer of Medicare Advantage

      WILMINGTON, Del., April 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced the appointment of Dr. Shelly Gupta as Chief Medical Officer ("CMO"). Dr. Gupta will oversee Clover's innovative clinical operations, quality initiatives, pharmacy operations, and precision-based chronic disease management programs, directly focusing on patient choice, provider autonomy, and delivering transparent, value-driven healthcare. Dr. Gupta brings extensive healthcare experience to Clover as a trained family practice physician with over a decade of experience in Medicare Advantage leadership and a proven record of enhanc

      4/7/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $AMST
    $CLOV
    $GOOG
    $GOOGL
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

      The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

      6/20/24 6:36:05 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $AMST
    $CLOV
    $GOOG
    $GOOGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      11/12/24 2:31:31 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      11/4/24 11:25:56 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Alphabet Inc. (Amendment)

      SC 13G/A - Alphabet Inc. (0001652044) (Subject)

      2/14/24 5:02:00 PM ET
      $GOOGL
      Computer Software: Programming Data Processing
      Technology